inclusion until the day preceding surgery (maximum 28 days therapy). The primary study outcome is to evaluate safety and tolerability of MRx0518 monotherapy in treatment naïve patients. Additional exploratory outcomes include identifying surrogate biomarkers of efficacy, microbiome analysis, effect on metabolic markers and identification of histological and genomic alterations in paired pre-treatment (diagnostic biopsy) and post-treatment (surgical specimen) samples.

**Results** In part A, 17 patients received treatment, across tumour groups including breast (n=8), prostate (n=4), uterine (n=3), melanoma (n=1) and bladder (n=1). MRx0518 was well tolerated by all, with no grade 3/4 CTCAE toxicity reported, no severe adverse effects or treatment discontinuations. All patients proceeded to surgery, however the COVID-19 pandemic delayed surgery in 3 cases.

Analysis of the first 5* patient paired samples utilising the NanoString Pan Cancer IO 360TM Gene Expression panel has demonstrated significant changes in gene expression profiles in 48 genes (p

**Conclusions** This study has demonstrated the safety and tolerability of the live biotherapeutic MRx0518 in treatment naïve cancer patients. Exploratory analyses of post-treatment samples has echoed preclinical observations of increased infiltration of immune cells following treatment and will undergo further validation. Part B will focus on investigating efficacy in a further 100 treatment naïve patients with a placebo-controlled arm.

**Trial Registration** NCT03934827

**Ethics Approval** The study was approved by East of England - Cambridge East Research Ethics Committee approval number 18/EE/0091.

**REFERENCE**


*Data analysis has been censored at 18/9/2020, further samples analysis is ongoing and will be updated.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0805

**806 CHANGES IN T CELL CLONALITY IN AWARE-1 STUDY, A WINDOW-OF-OPPORTUNITY STUDY WITH ATEZOLIZUMAB AND THE ONCOLYTIC VIRUS PELAREOREP IN EARLY BREAST CANCER**

**Luis Manso, 1Patricia Villagrasa, 2Nuria Chic, 3Begoña Bermejo, 4Juan Cevallos, 5Yann Iarzagaza, 6Blanca Carro, 7Salvador Blach, 8Mireia Margelí, 9Jose Alonso, 10Alejandro Martínez, 11Rafael Villanueva, 12Juan Guerra, 13Raquel Andrés, 14Pilar Zamora, 15Esteban Nogales, 16Manel Juan, 17Blanca González-Farre, 18Thomas Heineman, 19Gerard Nuño, 20Gergy Wilkinson, 21Matt Coffey, 22Azucena González, 23Délora Martínez, 24Laia Paré, 25Fernando Salvador, 26Xavier González, 27Alix Prat, 28Joaquín Gavilán. 29Hospital Universitario 12 de Octubre, Madrid, Spain; 30SÓLTI Breast Cancer Research Group, Barcelona, Spain; 31Hospital Clinic de Barcelona, Barcelona, Spain; 32Hospital Clínico Universitario de Valencia, Valencia, Spain; 33Hospital Universitario Fundación Jiménez, Madrid, Spain; 34Hospital Universitat Puerta de Hierro, Madrid, Spain; 35Instituto Valenciano de Oncología (IVO), Valencia, Spain; 36Institutos Catalá d’Oncologia, Barcelona, Spain; 37Hospital Clínico Universitario Virgen de, Murcia, Spain; 38Hospital Universitat Quirón Dexeus, Barcelona, Spain; 39Hospital Moisés Brogigi, Sant Joan Despi, Barcelona, Spain; 40Hospital Universitario de Fuenlabrada, Madrid, Spain; 41Hospital Clínico Universitario Lozano Bé, Zaragoza, Spain; 42Hospital Universitario La Paz, Madrid, Spain; 43Hospital Universitario Virgen Macarena, Sevilla, Spain; 44NanoString Technologies Inc, San Diego, CA, USA; 45Ohio State University, Columbus, OH, USA; 46Hospital Universitari General de Cataluña, Sant Cugat del Vallés, Spain.

**Background** A previous phase 2 study in metastatic breast cancer demonstrated a statistically significant improvement in overall survival (OS) in patients treated with pelareorep (pela) in combination with paclitaxel (PTX) versus PTX alone.1 Given that pela is an intravenously delivered immuno-oncolytic reovirus, we hypothesized that the OS benefit from pela + PTX may be attributed to an adaptive T cell response triggered by pela. To examine if pela can mediate the priming of an anti-tumor immune response, we are conducting together with the SOLTI group the AWARE-1 study (a window-of-opportunity study of pela in early breast cancer), which is currently enrolling and for which initial translational research results are presented.

**Methods** AWARE-1 is a window-of-opportunity study to evaluate the safety and effect of pela ± atezolizumab on the tumor microenvironment (TME) in 38 women with early breast cancer. Patients are treated with pela on days 1, 2, 8, and 9, while atezolizumab is administered on day 3. Tumor biopsies are collected at diagnosis, day 3, and day ~21. Five cohorts will be examined: Cohort 1: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole; Cohort 2: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole + atezolizumab; Cohort 3: TNBC (6 patients) receiving pelareorep + atezolizumab; Cohort 4: HER2+/HR+ (6 patients) receiving pelareorep + trastuzumab + atezolizumab; Cohort 5: HER2+/HR- (6 patients) receiving pelareorep + trastuzumab + atezolizumab. The primary endpoint of the study is CeTIL score [2], a metric for quantifying the changes in tumor cellularity and infiltration of TILs, where an increase in CeTIL is associated with a favorable response to treatment. Tumor tissue is being examined for pela replication, and changes to the TME are being assessed by immunohistochemistry and T cell receptor sequencing (TCR-seq). Peripheral blood is also being examined by TCR-seq.

**Results** Detailed TCR-seq results from peripheral blood and tumor tissue are presented for the ten-patients enrolled into Cohort 1 who received pela and letrozole. In tumor tissue, T cell clonality increased in day 21 biopsies relative to baseline biopsies, with similar increases in T cell fraction (the number of T cells) in the majority of patients. In general, most of the tissue-expanded T cell clones were also seen in the peripheral blood.

**Conclusions** Overall, these preliminary data from cohort 1 of AWARE-1 demonstrate that pela mediates priming of a T cell-based immune response that occurs both systemically and within breast cancer tissue.

**Trial Registration** NCT04102618

**Ethics Approval** This study was approved by the Spanish Health Authority, protocol number 2018-003345-42.

**REFERENCES**


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0806